Security record · archived quarter
DFTX
Definium Therapeutics, Inc. · Healthcare · Biotechnology
3Tracked holders
+2Δ holders
3.29MShares held
$44.05MReported value
+2New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2025
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 105 | +21 | 65.34M | $3.02B | +25 | −4 |
| Q1 2026 | 86 | +82 | 40.74M | $769.71M | +82 | — |
| Q4 2025 | 3 | +2 | 3.29M | $44.05M | +2 | — |
Who holds it · Q4 2025
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Marshall Wace ✦ | 2.98M | New | $39.84M | 0.0% | New | 1 | SEC ↗ |
| 2 | Marshall Wace ✦ | 2.98M | New | $39.84M | 0.0% | New | 1 | SEC ↗ |
| 3 | Marshall Wace ✦ | 2.98M | New | $39.84M | 0.0% | New | 1 | SEC ↗ |
| 4 | Ensign Peak Advisors, Inc | 262.00K | — | $3.51M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 52.23K | New | $700,000 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $39.84M | 0.0% |
| Marshall Wace | $39.84M | 0.0% |
| Marshall Wace | $39.84M | 0.0% |
| T. Rowe Price | $700,000 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 244 holders, 74.15M shares, $1.40B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Aug 14
SC 13G/A — DRIEHAUS CAPITAL MANAGEMENT LLC
Aug 14
SC 13G/A — Commodore Capital LP
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q4 2025 ·
Methodology ·
Get this via the API